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Background: The purpose of the PROLUCA study is to investigate the efficacy of preoperative and early
postoperative rehabilitation in a non-hospital setting in patients with operable lung cancer with special focus on
exercise.
Methods: Using a 2x2 factorial design with continuous effect endpoint (Maximal Oxygen Uptake (VO2peak)), 380
patients with non-small cell lung cancer (NSCLC) stage I-IIIa referred for surgical resection will be randomly assigned
to one of four groups: (1) preoperative and early postoperative rehabilitation (starting two weeks after surgery);
(2) preoperative and late postoperative rehabilitation (starting six weeks after surgery); (3) early postoperative
rehabilitation alone; (4) today’s standard care which is postoperative rehabilitation initiated six weeks after surgery.
The preoperative rehabilitation program consists of an individually designed, 30-minute home-based exercise
program performed daily. The postoperative rehabilitation program consists of a supervised group exercise program
comprising cardiovascular and resistance training two-hour weekly for 12 weeks combined with individual
counseling. The primary study endpoint is VO2peak and secondary endpoints include: Six-minute walk distance
(6MWD), one-repetition-maximum (1RM), pulmonary function, patient-reported outcomes (PROs) on health-related
quality of life (HRQoL), symptoms and side effects of the cancer disease and the treatment of the disease, anxiety,
depression, wellbeing, lifestyle, hospitalization time, sick leave, work status, postoperative complications (up to
30 days after surgery) and survival. Endpoints will be assessed at baseline, the day before surgery, pre-intervention,
post-intervention, six months after surgery and one year after surgery.
Discussion: The results of the PROLUCA study may potentially contribute to the identification of the optimal
perioperative rehabilitation for operable lung cancer patients focusing on exercise initiated immediately after
diagnosis and rehabilitation shortly after surgery.
Trial Registration: NCT01893580
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Lung cancer is one of the most frequently occurring
cancer diagnoses with the highest mortality rate [1].
Lung cancer is divided into Small-Cell Lung Carcinoma
(SCLC) and Non-Small Cell Lung Carcinoma (NSCLC).
Surgery is at present the primary treatment for NSCLC.
According to the Danish Register of Lung Cancer 2011,
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reproduction in any medium, provided the orfollowing radical surgery for lung cancer [2]. Modern
surgical treatment includes both minimal invasive sur-
gery, e.g. video-assisted thoracoscopic surgery (VATS),
and open surgery such as thoracotomy. An increasing
proportion of lung cancer patients are operated by VATS
technique in both Europe and the US. At Copenhagen
University Hospital (Rigshospitalet), more than 60% of
all lung cancers patients are operated by VATS [2].
Improved surgical techniques combined with effective
adjuvant chemotherapy have led to a significant survival
benefit in individuals with NSCLC [3,4]. Postoperative
complications are experienced by 25% of the patientsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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tive complications during the first two weeks after sur-
gery has been reported to be dependent on different
factors, e.g. preoperative cardiorespiratory capacity, mea-
sured as VO2peak [1,5]. The physiological consequences
of ageing and inactivity combined with the cancer dis-
ease and the treatment of cancer result in a marked re-
duction in VO2peak and functional capacity [6-8]. Other
factors such as smoking [9], alcohol consumption [10],
nutritional status [11] and comorbidity [12] are predic-
tors of postoperative complications. The treatment of
NSCLC and other types of cancer is complex and poten-
tially lethal. Accordingly, side effects are now recognized
as a subject of major clinical importance [13]. The side
effects may comprise physical and psychological as well
as social distress with symptoms such as reduced cardio-
respiratory capacity, paresthesia, post-thoracotomy pain
syndrome, fatigue, anxiety, and depression [14-16]. The
late side effects are long-lasting or even chronic and
may result in restrictions in activity of daily living and
reduced quality of life [5,17-23].
A Cochrane systematic review from 2012 indicates
that exercise in patients with a variety of cancer diagno-
ses may have beneficial effects on HRQoL [24]. This is
supported by a Danish randomized controlled trial with
269 cancer patients (different diagnoses) according to
which patients receiving chemotherapy tolerate intensive
physical exercise and experience reduced fatigue, depres-
sion, and nausea [25]. In general, rehabilitation in cancer
patients based on physical exercise perioperatively has
been shown to increase HRQoL and physical activity,
and at the same time reduce the side effects of the treat-
ment [24,26-33]. There is consistent evidence from 27
observational studies that physical activity is associated
with reduced all-cause, breast cancer-specific, and colon
cancer-specific mortality [34].
Clinical studies of preoperative physical exercise in
patients with operable NSCLC are sparse. However, a
recent prospective feasibility study on 25 patients with
NSCLC reports that the patients tolerate 30 minutes of
preoperative intensive cardiovascular exercise 5 times/
week. The study finds that exercise significantly improves
VO2peak and 6MWD [35]. Two other studies indicate that
rehabilitation including preoperative exercise can im-
prove physical and psychological outcome in patients
with NSCLC [36,37].
The effect of postoperative physical exercise in patients
with lung cancer has been investigated briefly. The studies
differ in type of intervention, dose and timing of interven-
tion, and the research is primarily based on case studies
and studies with few and heterogeneous participants
[36]. Two non-randomized feasibility studies observed
that supervised moderate to high intensity cardiovascu-
lar exercise initiated four weeks after surgery is safe andfeasible for operable lung cancer patients. The interven-
tion consisted of three weekly cycling sessions for a
period of 14 weeks, and participation was associated
with a significantly improved HRQoL [38,39].
In a prospective study of 45 lung cancer patients, exer-
cise on ergometer bikes 30 minutes daily, initiated two
weeks after end of cancer treatment (including both sur-
gery and chemotherapy), was reported to result in a pro-
nounced improvement in exercise capacity and functional
status [40]. The results are confirmed by other studies
[41,42]. Another randomized study of 53 lobectomized
lung cancer patients showed retention of muscle strength
in the intervention group in which the patients partici-
pated in mobilization and strength exercise twice daily
during admission followed by a 12-week long home exer-
cise program. HRQoL (EORTC questionnaire) and phys-
ical capacity (measured by 6MWD) were unchanged [43].
Overall, these studies indicated that postoperative exercise
may have a positive effect on physical capacity and
HRQoL in NSCLC. A systematic review from 2011 con-
cluded that pre- and postoperative exercise is safe and
feasible for NSCLC patients and associated with a positive
effect on physical capacity and, to some extent, HRQoL
[26]. However, the main part of the studies quoted in the
review are small case series and the only randomized
study in the review observes no difference between the
intervention and the control group [26]. In summary, sev-
eral studies indicate that postoperative exercise of NSCLC
patients is safe and associated with improvement of fitness
and self-reported outcome such as HRQoL and fatigue
[27,44]. Positive effects of perioperative exercise interven-
tions are more pronounced with moderate- to vigorous-
intensity versus mild-intensity exercise programs. More
research is required to fully understand the potential effect
of exercise over time and to determine essential attributes
of exercise (mode, intensity, frequency, duration, and tim-
ing) by cancer type and cancer treatment [24].
To our knowledge the present Perioperative Rehabilita-
tion in Operation for LUng CAncer (PROLUCA) study is
the first study to investigate the clinical effects of pre- and
early postoperative rehabilitation in NSCLC patients. In
PROLUCA a randomized clinical trial, the efficacy of pre-
and early postoperative rehabilitation is compared with
the effect of rehabilitation initiated six weeks after surgery
(usual care) in a non-hospital setting.
The aim of PROLUCA is to identify the optimal tim-
ing of exercise to improve VO2peak in postoperative
NSCLC patients. The specific aims are: (1) comparison
of combined preoperative home-based exercise with
postoperative exercise regarding VO2peak and patient-
reported outcomes (PROs), (2) comparison of early
postoperative exercise (initiated as early as two weeks
after surgery) with usual care regarding VO2peak and
PROs.
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Participants and settings
The study will recruit and randomize 380 patients (95
patients/study arm) with histologically or cytologically
confirmed NSCLC, stage I-IIIa (TNM classification v. 7
[45]) or strong substantiated suspicion of NSCLC, referred
for surgery. All subjects are assigned for curative lung
cancer surgery at Department of Cardiothoracic Surgery,
Copenhagen University Hospital (Rigshospitalet). The in-
clusion and exclusion criteria are described in Table 1:
Subject Eligibility Criteria in the PROLUCATrial.Procedure
The study is conducted in accordance with the CONSORT
(Consolidated Standards of Reporting Trials) statement
for non-pharmacologic interventions and the Helsinki
Declaration [49]. Informed consent is obtained from all
participants prior to initiation of any study procedures.
The study is approved by The Danish National CommitteeTable 1 Subject eligibility criteria in the PROLUCA trial
Inclusion criteria
All subjects are assigned for
curative lung cancer surgery at
Department of Cardiothoracic
Surgery RT at Copenhagen
University Hospital (Rigshospitalet).
Screened for eligibility criteria at
Bispebjerg University Hospital and
Gentofte Hospital.
At least 18 years old.
Performance status 0–2 (WHO)
[46].
Capable of participating in the
described tests and intervention.
Living in the City of Copenhagen
or surrounding Municipalities.
Reside within driving distance of
Copenhagen Centre for Cancer
and Health and capable of
managing transportation as
necessitated by the clinic-based
assessments and supervised
exercise interventions.
Ability to read and understand
Danish.
Approval by primary surgeon. To examine for any
contraindication in participating in
physical exercise.
Exclusion criteria
Presence of metastatic disease or
surgical inoperability.
Diagnosis of Lung Cancer not
verified by histological diagnosis.
Cardiac disease [6,47]. Decompensated heart failure,




exercise testing as recommended
by the American Thoracic Society
and exercise testing guidelines for
cancer patients [48].on Health Research Ethics (H-3-2012-028) and the Danish
Data Protection Agency (2007-58-0015).
The study flow is presented in Figure 1 Study Flow
PROLUCA. Using a 4-arm, randomized design, potential
subjects will be identified and screened for eligibility and
informed about PROLUCA by the study research coor-
dinators at the involved hospitals (Bispebjerg University
Hospital and Gentofte Hospital). After referral to intended
curative lung cancer surgery at Copenhagen University
Hospital (Rigshospitalet), the subjects are contacted by
telephone and provided with a review of the study. If the
subjects accept to participate, the baseline assessment is
performed at Copenhagen Centre for Cancer and Health.
At baseline the following assessments are performed:
(1) PROs described in Table 2 Data Assessment Schedule
in the PROLUCA Trial, (2) anthropometric data, (3)
6MWD, (4) muscle strength (1RM in chest- and leg-
press machines), (5) pulmonary function test, and (6)
cardiopulmonary exercise test (VO2peak). All baseline
assessments will be completed as close to time of diag-
nosis as possible and repeated the day before surgery,
pre-intervention (6MWD, pulmonary function, FACT-L),
post-intervention, and at follow-up six months and one
year after surgery.
Group allocation (Randomization)
Following the successful completion of baseline assess-
ments, participants will be randomly allocated, on an in-
dividual basis, to one of the four exercise intervention
groups:
Group 1: Preoperative home-based exercise and post-
operative rehabilitation initiated as early as two weeks
after surgery.
Group 2: Preoperative home-based exercise and post-
operative rehabilitation initiated six weeks after surgery.
Group 3: Postoperative rehabilitation initiated as early
as two weeks after surgery.
Group 4: Postoperative rehabilitation initiated six weeks
after surgery (Usual practice as control group).
The random allocation sequences will be concealed
from all study personnel and performed by Copenhagen
Trial Unit, Centre for Clinical Intervention Research. A
permuted block design with allocation weight of 1:1:1:1
will be used to generate the treatment assignments.
Randomly allocated participants will remain in the same
group for the entire duration of the intervention, as
expressed in Figure 2 PROLUCA Study Timeline. To
ensure similarity of randomized groups at baseline, pa-
tient randomization will be stratified based on type of
surgery, VATS versus thoracotomy surgery.
Blinding
It is not possible to blind the participants to their actual
treatment allocation, since participants are aware whether
Figure 1 Study Flow PROLUCA.
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operative exercise starts two or six weeks after surgery. All
study personnel collecting data and doing the statistical
analyses of the data are, however, blinded to the patient al-
location, and the patients are strictly informed not to re-
veal their group allocation to the test personnel.Exercise training protocols (General considerations)
Preoperative exercise
The home-based exercise program is individually designed
for each of the participants randomized to a preoperative
intervention. The ultimate goal of the preoperative home-
based exercise program is to ensure that the patients
perform cardiovascular exercise of moderate-vigorous in-
tensity (~60-80% of maximum heart rate (HRmax)) for at
least 30 minutes every day until surgery. The preoperative
period varies in length and the intention is not to exceed
14 days. The preoperative exercise is monitored by a heart
rate sensor (Polar Team 2 System, with off-line transmit-
ters) and an exercise diary logbook.Postoperative rehabilitation
The postoperative intervention consists of a supervised
12-week rehabilitation program containing 24 group-
based exercise sessions, three individual counseling ses-
sions, and three group-based lessons in health-promoting
behavior. If the participants have special needs in terms
of smoking cessation, nutritional counseling or patient
education, this is offered too.
The postoperative physical exercise consists of an
individually prepared supervised strength exercise –
and a group-based cardiovascular exercise twice a
week (60 minutes/session) on non-consecutive days for
12 weeks, a total of 24 sessions, containing the follow-
ing elements:
Warm-up (five minutes) and cardiovascular exercise
(25 minutes) on ergometer bike (BODY BIKE Classic
Supreme©), individually prepared strength exercise
(25 minutes) carried out using five machines (Techno-
gym™), leg press, chest press, leg extension, pull to
chest, pull-down (upper body). The practical aim of
strength exercise is to complete three series of 5–12
Table 2 Data assessment schedule in the PROLUCA trial
Baselinea Flw-upb Flw-upc Flw-upd Flw-upe Flw-upf
Anthropometric data and cancer disease X X X X X
Physiological measurements
Cardiorespiratory capacity (VO2peak) X X X X X
Six- minute walk distance (6MWD) X X X X X X
One-repetition-maximum (1RM) X X X X X
Heart rate (HR), Blood pressure (BP) X X X X X
Spirometric (FEV1/FEV1%) X X X X X
Patient-reported outcome
Health-related quality of life (EORTC QLQ-C30, FACT-L) X X FACT-L X X X
Symptoms and side effects (EORTC–LC13) X X X X X
Anxiety and depression (HADS) X X X X X
Well-being (SF-36) X X X X X
Distress thermometer X X X X X
Lifestyle X X X X X
Sickness absence and work status X X X X X
Social support (MSPSS) X X X X X
Other measurements
Perioperative complications X (30 days) X (30 days)
Duration of hospitalization X (30 days) X (30 days)
Survival Histological diagnosis and TNM staging X
aBaseline (0 week).
bFlw-up (Follow-up): Preoperation (the day before surgery).
cFlw-up (Follow-up): Pre-intervention (2/6 weeks after surgery).
dFlw-up (Follow-up): Post-intervention (14/18 weeks after surgery).
eFlw-up (Follow-up): Six months after surgery.
fFlw-up (Follow-up): One year after surgery.
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cialists supervise the training program following the
recommended principles [50]. All exercise sessions will
include supervised breathing exercises combined with
stretching and relaxation techniques (five minutes). All
the cardiorespiratory exercise is designed such that
participants begin exercising at a low intensity (~50%-
60% of individually determined HRmax) which is sub-
sequently increased to more moderate to vigorous
intensity (~70%-80% of individually determined HRmax).Figure 2 PROLUCA Study Timeline (three intervention groups and onThe ultimate goal for the postoperative exercise is two
group-based exercise sessions per week, with a cardio-
respiratory intensity for the first four weeks at ~50-60%
of individual HRmax. The next eight weeks the intensity
increases to moderate-high intensity at ~70-90% of
individually determined HRmax. The heart rate will be
monitored continuously throughout the cardiorespiratory
exercise using heart rate monitors and software (Polar
Team2 Pro©). All interventions will be individually tai-
lored to each participant and following the principles ofe control group).
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adults as recommended by the American College of
Sports Medicine (ACSM) [50]. The ultimate goal for the
strength exercise program is to exercise with an inten-
sity of ~60-80% of 1 RM two times a week for 12 weeks.
To ensure progression every second week, the load is
progressively increased and the number of repetitions
are reduced starting out at 12 repetitions in three sets
progressing to 10 repetitions in three sets to a final of
eight repetitions in three sets. The progression is docu-
mented in a study exercise log file for registration of the
intensity of all sessions along with data on blood pres-
sure prior to exercise.
Adherence Considerations
To maximize adherence, several strategies will be
employed including telephone-based follow-ups. The
patients are provided free parking in front of the center
and transport expenses are covered. The high degree of
scheduling flexibility allows participants to perform test
at a convenient time and work around other competing
demands such as medical appointments, work, and family
commitments.
Study endpoints and assessments
Primary endpoint
VO2peak is evaluated by an incremental test using an
electromagnetically braked cycle ergometer (Lode Corival
Ergometer©). Inspired and expired gases are analyzed
breath-by-breath by a metabolic cart (JAEGER Master-
Screen CPX©). Subjects begin pedaling at seven watts and
resistance increases after a predefined 10 watts ramp
protocol until exhaustion or a symptom-limited VO2peak
is achieved (pain, dizziness, anxiety etc.). This regimen
has previously been demonstrated to be appropriate for
measuring VO2peak in prior studies in patients with
ankylosing spondylitis [51]. Other similar VO2peak pro-
tocols are found appropriate for measuring VO2peak in
NSCLC [38,39,52].
Secondary endpoints
Patient-reported outcomes (PROs) PROs will include
HRQoL, symptoms and side effects, anxiety and depres-
sion, well-being, distress, lifestyle, sickness absence, work
status, and social support. HRQoL is assessed using the
integrated system of the European Organization for Re-
search and Treatment in Cancer (EORTC) for assessing
the HRQoL of cancer patients participating in inter-
national clinical trials and devised through collaborative
research. The EORTC QLQ-C30 assesses patient symp-
toms and HRQoL in lung cancer patients [53]. Symptoms
and side effects will be assessed using the EORTC–LC13,
which is an additional page to the EORTC-QLQ specific-
ally designed to cover a wide range of lung cancer patientsvarying in disease stage and treatment modality [54].
EORTC measures single items and the scales range in
score from 0 to 100. A high scale score represents a
higher response level. A high score for a functional scale
represents a high/healthy level of functioning and a high
score for the global health status/quality of life repre-
sents a high HRQoL. However, a high score for a symp-
tom scale/item represents a high level of symptomatology
or problems [53,54].
HRQoL will also be assessed using the Functional As-
sessment of Cancer Therapy - Lung (FACT-L) scale that
contains four subscales for physical (7-items), functional
(7-items), emotional (6-items), social/family well-being
(7-items) plus a lung cancer specific subscale (15-items)
which will be summed to obtain the FACT-L score (all
42 items) [55].
General well-being is assessed using the 36-Item Short
Form Health Survey (SF-36), standard recall (four weeks).
The SF-36 includes eight scales measuring general health
with two summary scales; physical and mental component
scales [56,57]. To assess psychological well-being, the
Hospital Anxiety and Depression Scale (HADS) with 14
items will be administered, designed to measure general
anxiety and depression for use in investigations of pa-
tients with physical illness [58]. The distress thermom-
eter is a validated measure of distress and consists of a
single item, with responses ranging from 0 to 10 [59].
The Multidimensional Scale of Perceived Social sup-
port (MSPSS) is a 12-item scale assessing social support.
Each item is answered on a seven-point Likert scale,
from one: Very strongly disagree, to seven: Very strongly
agree. The scale yields three subscale scores, for Family,
Friends, and Significant Others, and a Total score, which
is confirmed in a confirmatory factor analysis [60]. In
other different cancer studies, all the above-mentioned
validated instruments were found appropriate and easy
to administer [35,52,59,61].
Physiological measurements
Physiological measurements will include: (1) functional
capacity, (2) pulmonary function, (3) cardiovascular O2
delivery, and (4) muscle strength. (1) functional capacity
will be measured by a six-minute walking distance
(6MWD) test carried out over a pre-measured distance
of 22 m and in accordance with the American Thoracic
Society (ATS) statement [62]. The 6MWD test has dem-
onstrated good reliability and validity in patients with
chronic obstructive lung disease [63], a patient group with
similar symptomatology and pathophysiology. (2) Pulmon-
ary Function will be determined by assessing the Forced
Expiratory Volume in one second (FEV1), and the FEV1%
which is the ratio of FEV1 to the Forced Vital Capacity
(FVC) using a Triple V digital volume sensor© connected
to JAEGER MasterScreen CPX©. All pulmonary function
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ing to the ATS guidelines [48]. (3) Arterial O2 Saturation
will be assessed at rest and continuously during exercise
using pulse oximetry (Nellcor, OxiMax N-65©), which
provides the most accurate non-invasive assessment of
blood arterial O2 saturation levels. Muscle strength is
measured by 1RM [64] using machines (Technogym™)
that includes leg press (lower extremity) and chest press
(pectoral muscles).
Disease-related outcomes
In all patients lung cancer subtype, stage and extent of
surgery will be related to the effect of exercise and re-
habilitation interventions.
Tracking and monitoring of adverse events
Tracking and monitoring of adverse events are assessed as
follows: (1) before every intervention- and test-session, all
patients will receive face-to-face supervision by a special-
ized trained cancer nurse discussing any potential negative
side effects of the intervention assignment. All injuries
and adverse events (e.g., knee pain, back pain) will be re-
corded as unintended events. In addition, heart rate and
blood pressure are recorded prior to every intervention




This randomized phase II trial will accrue 380 subjects
with operable NSCLC over an accrual period of ~2 years.
The present design consists of four intervention groups
of equal size, and it is assumed that no interaction occurs
between the groups. With the smallest clinical relevant
difference set at 2 mLO2
. kg-1 . min−1,95 participants are
required in each group (power: 80%), giving a total inclu-
sion of 380 patients.
For each of the primary and secondary endpoints, three
separate t-tests will be used to compare each experimental
arm to the control arm in mean change across time of the
endpoint. For each endpoint, the overall alpha level will be
controlled at a two-sided 0.05 by using Holm's procedure
[65]. That is, Holm's procedure first ranks the three p-
values from lowest to highest. The first (lowest) p-value
has to be less than 0.05/3 (0.0167) to be significant and
permit continuation to the other t-tests. The Holm's
procedure continues sequentially in this fashion using
alpha levels of 0.05/2 (0.025) and 0.05/1 (0.05) for the
remaining two t-tests, respectively. Power for this study
is defined as the probability that at least one of the three
t-tests of the arm effect on VO2peak is significant; in
other words, power is the probability that the first of
the 3 ordered t-tests are significant. We assume that
change in VO2peak will have a standard deviation of4.0 mL . kg-1 . min−1 as observed in previous research
[27,36]. Statistical power depends upon the configur-
ation of mean change in VO2peak across the 4 arms.
Thus, for example, 80% power is obtained when the
mean change in VO2peak across Arms 1, 2, 3, and 4 is
0.60, 0.60, 2.10, and 0.0 (mL . kg-1 . min−1), respectively.Analytic plan
The intention-to-treat analysis includes all randomized
participants in their randomly assigned allocations. The
intervention group assignment will not be altered based
on the participant's adherence to the randomly allocated
study arm. Patients who are lost-to-follow-up are included
in the analysis (intention to treat). For the primary ana-
lysis, a multiple regression model will be used to assess a
change in VO2peak on study group, the baseline value of
the endpoint, and other pertinent baseline variables that
may influence change in the study endpoints (e.g., co-
morbid conditions/medications, self-reported exercise his-
tory, age). Data from PROs will be presented as mean,
standard deviation (SD), median and inter-quartile range
(IQR) and all change scores (value at follow-up minus
value at baseline) will be presented with a 95% confidence
interval.Discussion
The aim of PROLUCA is to contribute with important
knowledge about the efficacy of pre- and early postop-
erative rehabilitation in patients with NSCLC in a non-
hospital setting.
The decision to target newly diagnosed patients with
NSCLC was primarily based on the fact that these pa-
tients are not often examined in relation to the effect of
rehabilitation, although they generally have a good per-
formance status and prognosis after surgery and adju-
vant chemotherapy. In consequence, the issue of NSCLC
survivorship is becoming an increasingly important aspect
of the multidisciplinary care of this patient group and the
demands for knowledge correspondingly important.
The need for rehabilitation becomes obvious by the
fact that NSCLC patients are subject to a marked decrease
in cardiorespiratory capacity due to a combination of age
and comorbidity and reinforced by the use of adjuvant
cancer treatment [6]. It is well known that good pre-
operative cardiorespiratory capacity leads to better post-
operative conditions resulting in less postoperative
complications in patients with NSCLC [1,5]. Further
studies are also warranted on other physical effects of
exercise and how to commit this group of cancer pa-
tients to a more active lifestyle.
Studies focusing on the effects of exercise interventions
pre- and postoperatively are required to fully understand
the potential effect of exercise over time. The optimal
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ation, and timing) have yet to be determined [24].
No published research in cancer rehabilitation has in-
vestigated the best timing of rehabilitation in patients
with NSCLC in a randomized clinical trial. Qualitative
studies have pointed out that cancer patients may ex-
perience transition points during time of illness to which
they are particularly vulnerable: (1) diagnosis, (2) oper-
ation and hospitalization, (3) transition from hospital to
daily life, and (4) return to daily life [66-72]. The timing
of rehabilitation has also been indicated to of import-
ance when it comes to motivation toward a healthier life
style in patients with a variety of cancer diagnoses [73].
The ‘teachable moment’ is a term used in e.g. research
in breast cancer patients describing the transition that
takes place when the patients are diagnosed. This transi-
tion can modify barriers and motivate the patient; thus
timing of rehabilitation is of great importance for the
outcome [74].
The PROLUCA study aims at revealing the impact
of timing of rehabilitation on VO2peak and health-
promoting behavior in patients with NSCLC. The effect
six months and one year after surgery is measured.
VO2peak is chosen as the primary endpoint as this test
provides the gold standard (direct) assessment of cardiore-
spiratory capacity [13]. In a hospital setting it would have
been interesting to test cardiorespiratory capacity as early
as two weeks postoperatively, but as the intervention in
PROLUCA is carried out in a non-hospital setting, this
is not possible due to safety reasons. According to the
Danish Health Act from 2007 the responsibility for re-
habilitation of all patients with a decrease in functional
capacity lies with the municipalities unless medical as-
sistance is needed. The same is true of patient-targeted
prevention.
The patients perform a VO2peak test preoperatively
and again after the intervention. The first test acts as a
surrogate parameter for the starting point, and PROLUCA
is therefore not capable of clarifying what happens to
VO2peak shortly after surgery. Research indicates that
VO2peak spontaneously recovers to a limited degree at ap-
proximately 3 months after surgery and stabilizes at ap-
proximately 6 months after pulmonary resection. Another
study finds a 13% decrease in VO2peak ~6 months after
surgery [75]. As this study compares the preoperative
VO2peak with postoperative VO2peak value 6 months
after surgery, the best estimate possible is chosen.
To obtain a patient population as close to normal daily
practice as possible where patients are suffering from a
variety of comorbidity, PROLUCA limits the amount of
exclusion criteria. This makes PROLUCA unique com-
pared to other studies whose selection of patients is dis-
tinct. Therefore the results of PROLUCA may contribute
importantly to daily clinical practice.With the increasing interest in the field of exercise-
oncology research, more studies are now focusing on the
application of exercise as a concomitant intervention
alongside anti-cancer therapies.
Summary
Even though rehabilitation, with focus on exercise, is
widely recommended to cancer patients, information
concerning timing and dose of exercise rehabilitation is
lacking when it comes to patients operated for NSCLC.
To our knowledge no previous studies have been pub-
lished in which postoperative rehabilitation is initiated
as early as two weeks after surgery for NSCLC. Further-
more, there is a distinct need for trials including NSCLC
patients, since this group of patients is especially vulner-
able due to a high burden of comorbidity, risk of relapse
of the cancer disease and consequences of both surgical
and oncological treatment. In addition, the patient popula-
tion included in PROLUCA is as close to those seen in
normal daily practice as possible. This makes PROLUCA
unique compared to other studies whose selection of pa-
tients is distinct, and the results of the PROLUCA study
may contribute importantly to daily clinical practice.
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